Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | MSR1 | P21757 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485590 | 0.87 | ALOX15 (0.43) | L3MBTL1ATMTDP1ALOX15ALDH1A1 | |
| SCHEMBL27955084 | 0.82 | L3MBTL1 (0.40) | L3MBTL1ATMTDP1ALDH1A1TSHR | |
| SCHEMBL6484526 | 0.76 | AOC3 (0.36) | L3MBTL1TDP1ALDH1A1TSHRKDM4E | |
| SCHEMBL6488668 | 0.74 | AOC3 (0.41) | L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL6491244 | 0.73 | AOC3 (0.47) | L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL21798440 | 0.73 | ATM (0.45) | L3MBTL1ATMTDP1ALOX15ALDH1A1 | |
| SCHEMBL21798456 | 0.73 | ATM (0.45) | L3MBTL1ATMTDP1ALOX15ALDH1A1 | |
| SCHEMBL21798435 | 0.73 | ATM (0.45) | L3MBTL1ATMTDP1ALOX15ALDH1A1 | |
| SCHEMBL21798451 | 0.73 | ATM (0.45) | L3MBTL1ATMTDP1ALOX15ALDH1A1 | |
| SCHEMBL4940586 | 0.73 | ALOX15 (0.52) | L3MBTL1ATMTDP1ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | L3MBTL1 2554/4885ATM 4239/4885TDP1 3859/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | L3MBTL1 2554/4885ATM 4239/4885TDP1 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.